Adverse thrombo-embolic events with newer tyrosine kinase inhibitors: a call to action for better risk stratification and monitoring

Eur J Prev Cardiol. 2022 Jul 20;29(9):1309-1311. doi: 10.1093/eurjpc/zwab055.
No abstract available

Publication types

  • Editorial
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive*
  • Protein Kinase Inhibitors / adverse effects
  • Risk Assessment
  • Taiwan
  • Thromboembolism* / diagnosis
  • Thromboembolism* / epidemiology
  • Thromboembolism* / etiology

Substances

  • Protein Kinase Inhibitors